// App-Quantinova.ai

CTNI-45 : RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCT

Researchers

Presenter

  • Sotirios Bisdas

Principal Investigators

  • Jai Grewal

  • Volker Stieber

  • Robert Cavaliere

  • Craig Devoe

  • Randy Jensen

  • Elise Brownell

  • Tina Runk

  • Diana Dupont-Roettger

Medical Centers

  • The Monter Cancer Center, Northwell Health Cancer Institute, Lake Success, NY, USA

  • IAG-Image Analysis Group, London, United Kingdom

  • Baptist MD Anderson Cancer Center, Jacksonville, FL, USA

  • Huntsman Cancer Institute, University of UT, Salt Lake City, UT, USA

  • Novant Health Forsyth Medical Center, Winston-Salem, NC, USA

  • NSPC, Brain and Spine Surgery, Long Island, NY, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • AR 67

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved